Glenmark Pharmaceuticals Limited

rs,

bruary 14, 2025 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

Rs. 33,876

uticals Ltd. All Rights Reserved Q3 FY25 Summary Consolidated Revenue • Consolidated Revenue of Rs. 33,876 Mn • YoY growth of 35.1% Regional Highlights • Europe Business YoY growth of 14.8% • • ROW repor

35.1%

d Q3 FY25 Summary Consolidated Revenue • Consolidated Revenue of Rs. 33,876 Mn • YoY growth of 35.1% Regional Highlights • Europe Business YoY growth of 14.8% • • ROW reported growth impacted by ad

14.8%

enue of Rs. 33,876 Mn • YoY growth of 35.1% Regional Highlights • Europe Business YoY growth of 14.8% • • ROW reported growth impacted by adverse India Business at Rs. 10,637 Mn currency movements

Rs. 10,637

Europe Business YoY growth of 14.8% • • ROW reported growth impacted by adverse India Business at Rs. 10,637 Mn currency movements “We delivered strong and sustained growth this quarter, driven by robust pe

17.7%

rth America business to gain momentum from FY26 onwards, supported by our growing Profitability 17.7% significant milestone with IGI presenting promising first clinical data • EBITDA at Rs. 6,002 Mn,

Rs. 6,002

bility 17.7% significant milestone with IGI presenting promising first clinical data • EBITDA at Rs. 6,002 Mn, with EBITDA margin of respiratory and injectable portfolio. Additionally, we reached a • PAT

Rs. 3,480

with EBITDA margin of respiratory and injectable portfolio. Additionally, we reached a • PAT at Rs. 3,480 Mn with PAT margin of 10.3% from our Phase 1 study of the trispecific TREAT™️ antibody, ISB 2001,

10.3%

tory and injectable portfolio. Additionally, we reached a • PAT at Rs. 3,480 Mn with PAT margin of 10.3% from our Phase 1 study of the trispecific TREAT™️ antibody, ISB 2001, Other Highlights • R&D Ex

Rs. 2,249

ase 1 study of the trispecific TREAT™️ antibody, ISB 2001, Other Highlights • R&D Expenditure of Rs. 2,249 Mn (6.6% of revenue) this asset.” at the 66th American Society of Hematology (ASH) Annual Meetin

6.6%

the trispecific TREAT™️ antibody, ISB 2001, Other Highlights • R&D Expenditure of Rs. 2,249 Mn (6.6% of revenue) this asset.” at the 66th American Society of Hematology (ASH) Annual Meeting. We co

300.2%

0,637 7,813 7,297 7,491 33,237 638 33,876 2,658 7,705 6,357 7,271 23,991 1,076 25,067 300.2% 1.4% 14.8% 3.0% 38.5% -40.7% 35.1% 12,817 -17.0% 7,405 6,874 7,041 34,137 201 34,338